Evidence map›Paper›PMID 33976609›Full record

ArticleTransfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie2021

Cryostorage to What End? - Autologous Stem Cell Products in Burkitt Lymphoma, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Myeloproliferative Neoplasm Patients.

Katharina Kriegsmann, Petra Pavel, Tilmann Bochtler, Anita Schmitt, Sandra Sauer, Mark Kriegsmann, Thomas Bruckner, Stefan Klein, Harald Klüter, Carsten Müller-Tidow and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Katharina KriegsmannDepartment of Hematology, Oncology, and Rheumatology, Heidelberg University, Heidelberg, Germany.
Petra PavelStem Cell Laboratory, IKTZ Heidelberg GmbH, Heidelberg, Germany.
Tilmann BochtlerDepartment of Hematology, Oncology, and Rheumatology, Heidelberg University, Heidelberg, Germany.
Anita SchmittDepartment of Hematology, Oncology, and Rheumatology, Heidelberg University, Heidelberg, Germany.
Sandra SauerDepartment of Hematology, Oncology, and Rheumatology, Heidelberg University, Heidelberg, Germany.
Mark KriegsmannInstitute of Pathology, Heidelberg University, Heidelberg, Germany.
Thomas BrucknerInstitute of Medical Biometry und Informatics, Heidelberg University, Heidelberg, Germany.
Stefan KleinDepartment of Medicine III, University Medical Center Mannheim (UMM), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Harald KlüterInstitute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, German Red Cross Blood Service Baden-Württemberg-Hessen, Mannheim, Germany.
Carsten Müller-TidowDepartment of Hematology, Oncology, and Rheumatology, Heidelberg University, Heidelberg, Germany.
Patrick WuchterInstitute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, German Red Cross Blood Service Baden-Württemberg-Hessen, Mannheim, Germany.
Heidelberg University · DEGerman Cancer Research Center · DEGerman Red Cross · DEHeidelberg Institute for Stem Cell Technology and Experimental Medicine · DEUniversity Medical Centre Mannheim · DEZimmer Biomet (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRecently, we identified a huge discrepancy between the collection practice and the actual utilization of cryopreserved peripheral blood stem cells (PBSCs) for high-dose chemotherapy (HDCT) and autologous blood stem cell transplantation (ABSCT). Specifically, patients with Burkitt lymphoma, acute leukemia, and myeloproliferative neoplasms (MPN) were frequently not referred for ABSCT after successful PBSC collection.

objectiveThe aim of this study was to identify variables that are associated with the non-utilization of PBSC grafts.

methodsWe retrospectively analyzed the collection, storage, and disposal of PBSC grafts in Burkitt lymphoma (

resultsNone of the Burkitt lymphoma patients were referred for ABSCT. Only in 1 (6%) patient, the graft was discarded after the patient's death. In all other patients (

conclusionsAs the role and efficacy of autologous HDCT/ABSCT are not established in the analyzed entities, the indication for PBSC collection should be reanalyzed in regular intervals. Moreover, PBSC grafts from patients who have deceased, have insufficient grafts, or have already undergone an allogeneic TPL should be considered for disposal or (if applicable) for research use, to economize storage costs on a rational basis.

Indexed as

Autologous blood stem cell transplantationCryopreservationPeripheral blood stem cellsTransplantation

Identifiers

PMID33976609
PMCPMC8077354
OpenAlexW3151250055

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.